[The levels of HBsAg can predict the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil, in HBeAg-positive chronic hepatitis B patients].
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
; 25(2): 132-4, 2011 Apr.
Article
en Zh
| MEDLINE
| ID: mdl-21863639
ABSTRACT
OBJECTIVE:
To investigate the levels of HBsAg in predicting the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil (ADV), in HBeAg-positive chronic hepatitis B patients.METHODS:
This trial enrolled 62 HBeAg-positive chronic hepatitis B patients with detectable HBsAg for at least 6 months prior to screening, serum HBV DNA levels of at least 100 000 IU/ml. The efficacy assessment viral suppression below 100 IU/ml. The patients with HBV DNA < or = 100 IU/ml after 24 weeks therapy were divided into group A, in which monotherapy continued; While the rest were divided into group B, in which ADV was combined until week 48. In group B, at the end-of-treatment, the patients with HBV DNA < or = 100 IU/ml were divided into group B1, the rest were divided into group B2.RESULTS:
There was no significant difference on the baseline characteristics of patients between B1 and B2. There was significant difference on the levels of HBsAg at 12-week and 24-week between B1 and B2; while there was no significant difference on the levels of HBeAg.CONCLUSIONS:
The levels of HBsAg at 12-week and 24-week would be predictors to evaluate the efficacy of combined therapy in HBeAg-positive chronic hepatitis B patients.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Adenina
/
Interferón-alfa
/
Hepatitis B Crónica
/
Organofosfonatos
/
Antígenos e de la Hepatitis B
/
Antígenos de Superficie de la Hepatitis B
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
Zh
Revista:
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
Asunto de la revista:
VIROLOGIA
Año:
2011
Tipo del documento:
Article
País de afiliación:
China